In this article, we will look at the 10 Best 52-Week Low Blue Chip Stocks to Buy Right Now.

The S&P 500 has performed exceedingly well over the past two years, powering to all-time highs amid easing inflation and the artificial intelligence boom. Despite the 24% and 14% gains over the past two years, respectively, not every company has had a great time over the same period.

While some stocks are flirting with record highs after blockbuster gains, others have pulled back significantly and are trading close to their 52-week lows. The stocks have pulled back due to a series of headwinds, including concerns about the economic outlook, monetary policy uncertainty, and deteriorating consumer spending power.

Nevertheless, analysts at Goldman Sachs expect the global bull market to continue, helped by an improving earnings outlook and continued economic growth. Markets have also been reacting to the nomination of Kevin Warsh to succeed current chair Jerome Powell.

“Given this macro backdrop, it would be unusual to see a significant equity setback/bear market without a recession, even from elevated valuations,” said Peter Oppenheimer, Goldman Sachs Research’s chief global equity strategist.

Head of the Applied Equity Advisors Team at Morgan Stanley Investment Management, Andrew Slimmon, expects stocks to edge higher in 2026, thanks to the Fed’s supportive monetary policy. The fact that bull markets last five to seven years also supports the thesis, given that we are in the fourth year of the current bull cycle.

Amid the improving investment environment, let’s take a look at some of the Best 52-Week Low Blue Chip Stocks to Buy Right Now that are trading at a great discount after a deep pullback.

Our Methodology

To curate the Best 52-Week Low Blue Chip Stocks to Buy Right Now, we sifted through blue chip ETFs and compiled a list of their holdings. From the list, we identified stocks trading within 0-5% of their 52-week lows and with an upside potential of more than 20%. We also detailed the number of hedge funds holding stakes in them in the third quarter of 2025. Finally, we ranked the stocks in ascending order of the upside potential.

Note: The data is of February 4

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

Best 52-Week Low Blue Chip Stocks to Buy Right Now

10. Crown Castle Inc. (NYSE:CCI)

Share Price: $86.81

52-Week Range: $83.21 – $115.76

Number of Hedge Fund Holders: 56

Stock Upside Potential: 24.40%

Crown Castle Inc. (NYSE:CCI) is one of the best blue-chip stocks with a 52-week low to buy right now. Crown Castle Inc. (NYSE:CCI) released its fourth-quarter 2025 earnings on February 4, highlighting a company in the midst of a major shift as it moves forward with plans to sell off its fiber and small cell businesses. The company’s EPS came in at $0.67, beating the estimates by $0.12, while revenue was $1.07 billion, slightly exceeding expectations. The company is cutting roughly 20% of its workforce as it prepares to sell its fiber business, with the layoffs and other cost-cutting measures expected to save about $65 million annually.

For the full year 2025, Crown Castle surpassed its financial targets across all key metrics. Site rental revenue reached $4.05 billion, adjusted EBITDA totaled $2.86 billion, and adjusted funds from operations (AFFO) came in at $1.90 billion, all exceeding guidance. The year’s results were fueled by 4.9% organic growth, excluding the impact of Sprint churn, demonstrating strong operational performance despite challenges in the industry.

Looking ahead, the company expects pressure in 2026 from DISH terminations and Sprint cancellations, forecasting declines in site rental revenue and adjusted EBITDA. However, AFFO is projected to edge higher on lower interest costs and cost-cutting initiatives. Crown Castle plans to maintain its $4.25 annual dividend, repurchase $1 billion in shares, and reduce debt by $7 billion, with management viewing 2026 as a growth trough and anticipating improved momentum in 2027 and beyond.

Crown Castle Inc. (NYSE:CCI) is a leading real estate investment trust (REIT) and provider of shared communications infrastructure in the U.S., owning and operating over 40,000 cell towers and 85,000+ route miles of fiber. The company enables mobile connectivity by leasing space on these towers and supporting small-cell networks for carriers, including 5G and other technologies.

9. Abbott Laboratories (NYSE:ABT)

Share Price: $109.30

52-Week Range : $105.27- $141.23

Number of Hedge Fund Holders: 68

Stock Upside Potential: 27.21%

Abbott Laboratories (NYSE:ABT) is one of the best 52-week low blue-chip stocks to buy right now. Reuters reported on February 4 that Abbott Laboratories (NYSE:ABT) has logged 860 serious injuries tied to the recall of certain FreeStyle Libre 3 and Libre 3 Plus glucose monitoring sensors, based on the U.S. Food and Drug Administration data through January 7. That figure is up from 736 severe adverse events and seven deaths disclosed in November.

The FDA issued an early alert on December 2 and later classified the matter as a Class I recall on January 14, its most serious category. Abbott had cautioned that defective sensors could produce inaccurate glucose readings, potentially leading patients to delay or skip insulin doses. The company said the problem was traced to a single production line and has since been resolved.

On January 23, UBS reiterated a Buy rating on Abbott Laboratories and set a $158 price target. The bullish stance underlines the research firm’s confidence in the company’s prospects, despite recent concerns about lower-than-expected fourth-quarter results.

There are growing concerns about the company’s 2026 organic sales growth of about 7%, following its 3.8% organic sales growth. UBS said that despite a sales miss, Abbott showed financial resilience, posting earnings of $1.50 per share in line with expectations and guiding to 2026 EPS of $5.55 to $5.80, broadly in line with consensus at the midpoint. UBS expects the company to return to high single-digit organic growth, including the reacceleration of the electrophysiology business in the US.

The company’s revenue base is also expected to benefit from the launch of the Volt Pulsed Field Ablation System. The research firm also expects the stock to receive a boost from the upcoming clinical trial for left atrial appendage closure. It also expects Abbott Laboratories to be one of the primary beneficiaries of continuous glucose monitoring becoming the standard of care in diabetes over the next three years.

Abbott Laboratories (NYSE:ABT) is a global healthcare company that researches, develops, and manufactures medical devices, diagnostic tools, branded generic medicines, and nutritional products.

8. T-Mobile US Inc. (NASDAQ:TMUS)

Share Price: $197.21

52-Week Range: $181.36 – $276.49

Number of Hedge Fund Holders: 81

Stock Upside Potential: 29.27%

T-Mobile US (NASDAQ:TMUS) is one of the best blue-chip stocks with a 52-week low to buy right now. On February 3, Amdocs said it will extend its long-running partnership with T-Mobile US (NASDAQ:TMUS) through a new multi-year agreement to support the carrier’s expansion and operational priorities across both consumer and business markets.

The deal includes managed services, software development, and work on AI-driven innovation, such as generative AI applications, along with integration projects tied to UScellular. Amdocs has been a key technology partner for T-Mobile for years, helping to strengthen its 4G LTE and 5G networks, and this extension continues that collaboration.

On January 21, analysts at Benchmark reiterated a Buy rating and a $295 price target on T-Mobile US. The positive stance comes on the heels of the research firm reiterating T-Mobile US as its 2026 Benchmark Best idea, following a 33% pullback from a 12-month high. According to the research firm, the company boasts network advantages and prospects for increased penetration in non-top-100 US markets and among corporate users.

T-Mobile US Inc. (NASDAQ:TMUS) provides wireless, messaging, high-speed 5G data, and home broadband services to over 140 million subscribers.

7. Equifax Inc. (NYSE:EFX)

Share Price: $201.40

52-Week Range: $199.63 – $281.03

Number of Hedge Fund Holders: 43

Stock Upside Potential: 31.14%

Equifax Inc. (NYSE:EFX) is one of the best 52-week low blue chip stocks to buy right now. Equifax Inc. (NYSE:EFX) reported strong fourth-quarter and full-year 2025 results on February 4, with Q4 revenue climbing 9% year over year to $1.55 billion, beating guidance even as U.S. hiring and mortgage markets remained sluggish. The performance was broad-based, with U.S. Mortgage revenue jumping 20%, Workforce Solutions up 9%, and USIS climbing 12%. International operations also contributed, rising 5% in local currency, led by strength in Latin America.

For the full year, Equifax generated $1.13 billion in free cash flow, an increase of nearly 40%. In the fourth quarter alone, the company returned $561 million to shareholders, including $500 million in share repurchases. Executives pointed to continued progress on the EFX2028 strategy, which emphasizes innovation, margin expansion, and stronger cash generation as the business transitions beyond its cloud transformation.

Looking to 2026, management issued an optimistic outlook, projecting revenue of $6.72 billion, up about 10.5%, and adjusted EPS of $8.50, an 11% gain year over year. The forecast factors in a slight decline in the U.S. mortgage market but anticipates margin improvement as customers adopt updated credit scoring models. Alongside the earnings release, Equifax announced an expanded partnership with Gen Digital to bolster consumer identity protection and financial wellness tools, promising more personalized offerings for myEquifax users.

Equifax Inc. (NYSE:EFX) is a global data, analytics, and technology company that gathers and analyzes data on over 800 million consumers and 88 million businesses. It helps financial institutions, employers, and governments assess creditworthiness, manage risk, verify income/employment, and prevent fraud.

6. Roper Technologies, Inc. (NASDAQ:ROP)

Share Price: $351.00

52-Week Range: $345.93 – $595.17

Number of Hedge Fund Holders: 63

Stock Upside Potential: 32.38%

Roper Technologies Inc. (NASDAQ:ROP) is one of the best blue-chip stocks with 52-week lows to buy right now. On January 29, Goldman Sachs reiterated a Buy rating but cut its price target on Roper Technologies Inc. (NASDAQ:ROP) to $440 from $477.

The price target cut follows the fourth-quarter 2025 report, in which overall segment EBITDA came in below expectations. While the Technology Enabled segment EBITDA came 1% above consensus estimates, the Application Software and Network Software segments missed expectations by 1% and 2%, respectively.

Nevertheless, the research firm maintains a Buy stance, as all three segments posted mid-single-digit sales growth, with organic growth of about 4% in Application Software. The Network Software segment delivered 5% organic growth, with Technology Enabled Products increasing by 5%.

In addition, the company issued solid guidance with expected earnings per share of $21.30 to $21.55 for 2026. The company is also projecting organic growth of between 5% to 6%.

Similarly, Raymond James reiterated a Strong Buy rating on the stock and also cut the price target to $500 from $575. The price target cut is in response to the company’s touted yet imperfect fourth-quarter 2025 results.

Roper Technologies, Inc. (NASDAQ:ROP) is a diversified technology company that acquires and manages niche-market software and technology-enabled product businesses. It focuses on high-margin, recurring revenue, with over three-fourths of its revenue derived from software, serving sectors like healthcare, transportation, and education.

5. ​JD.com, Inc. (NASDAQ:JD)

Share Price: $27.32

52-Week Range: $27.16 – $46.44

Number of Hedge Fund Holders: 55

Stock Upside Potential: 37.37%

JD.com Inc. (NASDAQ:JD) is one of the best 52-week low blue-chip stocks to buy right now. On January 27, Reuters reported that Chinese logistics infrastructure company Jingdon Property has filed for an Initial Public Offering. JD.Com Inc. (NASDAQ:JD) owns a majority stake in a company that develops and manages infrastructure assets, primarily logistics parks.

Jingdong plans to use net proceeds from the offering to expand its overseas infrastructure asset network and strengthen its footprint in Chinese cities. Following the listing, JD.com will remain the majority shareholder with its 75% stake. Other notable shareholders in the unit include Hillhouse and Warburg Pincus.

Earlier on January 26, analysts at BofA Securities lowered JD.com’s price target to $36 from $38 and reiterated a Buy rating. The price target adjustment comes amid concerns that the company’s fourth-quarter 2025 results, scheduled for release in March, will show a 3.1% year-over-year decline in direct sales, driven by a 13% drop in home appliance and electronics sales.

However, the slump in direct sales should be offset by continued mid-teens growth in general merchandise sales. In addition, Marketplace and other service revenue is expected to rise 26% year over year. Therefore, total revenue is expected to increase by 2.6% year over year.

​JD.com, Inc. (NASDAQ:JD) is a premier Chinese e-commerce giant and technology-driven supply chain service provider. It operates a massive direct-sales platform, providing consumers with electronics, home appliances, and general merchandise, supported by an advanced, self-owned logistics network that delivers 90% of orders on the same or next day.

4. Netflix, Inc. (NASDAQ:NFLX)

Share Price: $80.87

52-Week Range: $79.23 – $134.12

Number of Hedge Fund Holders: 154

Stock Upside Potential: 42.44%

Netflix Inc. (NASDAQ:NFLX) is one of the best blue-chip stocks with a 52-week low to buy right now. On January 27, Reuters reported that the U.S. Senate Judiciary Committee planned a hearing on Netflix’s (NASDAQ:NFLX) proposed acquisition of Warner Bros., a deal that could reshape the streaming industry. Scheduled for February 3, the hearing was set to examine how the merger might affect competition, with Netflix gaining access to franchises like Friends and Batman and the HBO Max platform. The deal has also drawn attention in the UK over concerns it could strengthen Netflix’s dominance.

Netflix originally offered $83 billion in cash and stock, but later revised the deal to an all-cash offer to address investor concerns over its volatile share price. This move put additional pressure on rival bidder Paramount Skydance, whose offer Warner Bros. Discovery rejected as riskier.

During the February 3 hearing, senators questioned Netflix Co-CEO Ted Sarandos about the $82.7 billion acquisition. Led by Senator Mike Lee, lawmakers warned the merger could reduce consumer choice, cut entertainment jobs, and limit competitors’ access to Warner Bros.’ content, further boosting Netflix’s market power. The Justice Department is reviewing the deal alongside Paramount Skydance’s bid amid intensifying scrutiny over its impact on the streaming market.

On January 21, Needham cut Netflix’s price target to $120 from $150 but kept a Buy rating, citing $275 million in expected legal and regulatory costs in 2026 that could weigh on margins and free cash flow, while highlighting strong content plans and growing subscriber retention. The same day, Deutsche Bank raised its price target to $98 from $95 with a Hold rating, noting solid Q4 results but flagging operating income pressure from the Warner Bros. deal.

Netflix, Inc. (NASDAQ:NFLX) is a global streaming service that produces and licenses content and offers subscription plans, including ad-supported options.

3. Charter Communications, Inc. (NASDAQ:CHTR)

Share Price: $206.12

52-Week Range: $108.38-$437

Number of Hedge Fund Holders: 53

Stock Upside Potential: 47.09%

Charter Communications Inc. (NASDAQ:CHTR) is one of the best blue-chip stocks with a 52-week low to buy right now. On January 29, Charter Communications Inc. (NASDAQ:CHTR) reiterated its plans to focus on messaging the utility and value of its products and services to customers. It also plans to deliver sustainable, long-term customer EBITDA and cash flow growth for shareholders.

The remarks follow the delivery of mixed fourth-quarter and full-year 2025 results. The company reported a smaller-than-expected quarterly decline in broadband subscribers, losing 119,000 internet customers, fewer than the 131,970 expected. In addition, it added 44,000 video subscribers, helped by simpler pricing options and bundled packages, compared to a loss of 123,000 subscribers last year.

Total revenues in the fourth quarter were down 2.3% year over year to $13.6 billion. Charter’s Q4 2025 net income was $1.3 billion, down from $1.5 billion a year earlier, reflecting lower Adjusted EBITDA, Cox merger-related costs, and higher taxes. However, they were offset by an increase in residential mobile service revenue.

Charter Communications, Inc. (NASDAQ:CHTR) is a leading American broadband connectivity company and cable operator, operating under the Spectrum brand. It provides internet, TV, mobile, and voice services to over 57 million residential and business customers across 41 states.

2. Sanofi (NASDAQ:SNY)

Share Price: $47.04

52-Week Range: $44.62 – $60.12

Number of Hedge Fund Holders: 32

Stock Upside Potential: 66.73%

Sanofi (NASDAQ:SNY) is one of the best 52-week low blue-chip stocks to buy right now. On January 29, Sanofi SA (NASDAQ:SNY) reiterated plans to conduct a €1 billion share buyback in 2026. The buyback push comes as the company delivered a strong Q4 2025.

Sanofi posted strong fourth-quarter results, driven by surging demand for its asthma drug Dupixent, which it co-developed with Regeneron (REGN). Adjusted earnings per share came in at €1.53, while revenue climbed to €11.3 billion, both topping analyst forecasts. Dupixent sales jumped 32.2% to €4.2 billion, helping to offset a 2.5% drop in vaccine revenue, which slipped to €2 billion. Despite the upbeat report, Sanofi’s shares edged lower amid broader market volatility.

According to Chief Executive Officer Paul Hudson, profitable growth is expected to continue for at least 5 years. The remarks come as management is under pressure to show that the company’s pipeline can replace Dupixent’s revenues. The management team has already ramped up investment in research and development to support the ambition.

Sanofi (NASDAQ:SNY) is a major French-based multinational pharmaceutical and healthcare company that discovers, develops, manufactures, and markets pharmaceuticals, vaccines, and consumer healthcare products globally. Operating in over 60 countries, it specializes in immunology, oncology, rare diseases, and infectious diseases.

1. Veeva Systems Inc. (NYSE:VEEV)

Share Price: $203.92

52-Week Range: $201.54 – $310.50

Number of Hedge Fund Holders: 57

Stock Upside Potential: 67.07%

Veeva Systems (NYSE:VEEV) is one of the best 52-week low blue-chip stocks to buy right now. On January 29, Veeva Systems (NYSE:VEEV) unveiled Veeva eSource, a new Veeva SiteVault tailored to eliminate manual clinical trial processes and increase data quality. On January 13, Goldman Sachs cut its rating on Veeva Systems to Sell and set a price target of $215, citing concerns that the company may struggle to maintain its historic growth pace as some of its core products mature.

Analyst Adam Hotchkiss flagged rising competition in Veeva’s Commercial segment, particularly from Salesforce’s Life Sciences Cloud, and noted that visibility around growth from newer offerings remains limited. Although Veeva’s R&D solutions continue to show promise, Goldman Sachs believes the company will face hurdles in sustaining the high‑teens growth needed to hit its 2030 goals, leaving it less compelling compared with peers that offer stronger upside.

On January 8, Veeva Systems and BioMarin Pharmaceutical (NASDAQ:BMRN) announced they are expanding their long-term enterprise agreement, strengthening a partnership that has already been in place for several years. The renewed deal is designed to boost BioMarin’s efficiency and agility, while improving the overall experience for healthcare providers and patients through Veeva’s suite of software, data, services, and consulting capabilities.

BioMarin’s CEO, Alexander Hardy, described the agreement as an important milestone in the company’s digital transformation, noting that combining BioMarin’s scientific expertise with Veeva’s technology will help deliver breakthrough medicines to patients more quickly. Veeva CEO Peter Gassner highlighted the companies’ shared commitment to product excellence and customer success, adding that the expanded collaboration will further support BioMarin’s global mission to advance innovative therapies.

Veeva Systems Inc. (NYSE:VEEV) is a leading global provider of industry-specific, cloud-based software, data, and analytics for the life sciences (pharmaceutical, biotech, and medical device) industry.

While we acknowledge the potential of VEEV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VEEV and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Best Cheap Stocks to Buy for 2026 and 10 Stocks with Huge Growth Potential According to the Media.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.